A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

This is an open-label, single arm, dose escalation study in patients with advanced cancers.
Treatment will be administered on an outpatient basis.

Inclusion Criteria:

- Histologically or cytologically confirmed solid tumors or lymphomas that is metastatic
or unresectable and for which standard curative or palliative measures do not exist or
are no longer effective

- 18 years or older

- ECOG performance status 0-1

- Life expectancy ≥ 3 months

- Evaluable disease

- Adequate organ functions

- 4 weeks from prior chemotherapy ( 6 weeks for mitomycin C and nitrosourea) ,
immunotherapy, investigational anti-cancer therapy, radiation therapy; and have
recovered from prior toxicities

- At least 4 weeks from major surgery

- Agree to practice effective contraception

- Agree to follow protocol required evaluations

- Ability to understand and willingness to sign the informed consent form

Exclusion Criteria:

- Previously untreated CNS metastasis or progressive CNS metastasis

- Currently receiving radiotherapy, biological therapy, or any other investigational
agents

- Uncontrolled intercurrent illness

- Pregnant or lactating women

- Known to be HIV-positive

- Known active hepatitis B and/or hepatitis C infection